Management of patients with myocardial infarction and hypertension

European Heart Journal

Volumn 21, Issue 14, 2000, Pages 1125-1134

  Lip, G Y H ^a   Lydakis, C ^a   Beevers, D G ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; LABETALOL; LISINOPRIL; MAGNESIUM SULFATE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PROPANOL; TIMOLOL; VERAPAMIL;

CLINICAL TRIAL; EMERGENCY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BLOOD PRESSURE; CORONARY CARE UNITS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 0034661788     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.2206     Document Type: Review

References (82)

1. Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens. 2:1989;486-496.
2. Strandgaard S. Autoregulation of cerebral circulation in hypertension. Acta Neurol Scand. 57:1978;1-82.
3. Parmley WW, Thyberg JV. Determinants of myocardial oxygen demand. Yu PN, Goodwin JF. Progress in cardiology. 1976;19-34 Lea & Febiger, Philadelphia.
4. Rubio R, Berne RM. Regulation of coronary blood flow. Progr Cardiovasc Dis. 18:1975;105-121.
5. Hoffman JIE. Determination and prediction of transmural myocardial perfusion. Circulation. 58:1978;381-391.
6. Polese A, De Cesare N, Montorsi P. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 83:1991;845-853.
7. Strauer BE. Hypertension and the heart: Clinical studies. Zanchetti A, Tarazi RC. Handbook of hypertension, vol 7: Pathophysiology of hypertension. 1986;84-101 Elsevier, Amsterdam.
8. Strandgaard S, Haunso S. Why does antihypertensive treatment prevent stroke but not myocardial infarction? Lancet. ii:1987;658-661.
9. WHO Tech Rep Ser. 628:1978;57.
10. Kincaid Smith P. Malignant hypertension. J Hypertens. 9:1991;893-899.
11. Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med. 93:1993;92-110.
12. Sporl-Radun S, Betzien G, Kaufmann B, Liede V, Abshagen U. Effects and pharmacokinetics of isosorbide dinitrate in normal man. Eur J Clin Pharmacol. 18:1980;237-244.
13. Nemerovski M, Shah P. Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration. Cardiology. 67:1981;180-189.
14. Lydakis C, Chaudary AY, Lip GYH. The `Vaso-Vagal Effect' of Nitrates: An under-recognised complication of nitrate use. Int J Clin Pract. 52:1998;418-421.
15. Vidt DG, Gifford RW Jr. A compendium for the treatment of hypertensive emergencies. Cleve Clin Q. 51:1984;421-430.
16. Isles CG. Hypertensive emergencies. A: Malignant hypertension and hypertensive encephalopathy. Swales JD. Textbook of hypertension. 1994;1233-1248 Blackwell Scientific Publications, Oxford.
17. Lambert CR, Grady T, Hashimi W, Blakely M, Panayioutou H. Hemodynamic and angiographic comparison of intravenous nitroglycerin and nicardipine mainly in subjects without coronary artery disease. Am J Cardio. 71:1993;420-423.
18. Bertel O, Conen LD. Treatment of hypertensive emergencies with the calcium blocker nifedipine. Am J Med. 79:1985;31-35.
19. Guazzi M, Olivary MT, Polese A, Fiorentini C, Mafrini F, Moruzzi P. Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther. 22:1977;528-532.
20. Anonymous. Hypertensive emergencies (Editorial). Lancet. 338:1991;220-221.
21. Bertel O, Conen D, Radu EW, Muller J, Lang C, Dubach UC. Nifedipine in hypertensive emergencies. Br Med J. 286:1983;19-21.
22. Ellrodt AG, Ault MJ, Riedinger MS, Murata GH. Efficacy and safety of sublingual nifedipine in hypertensive emergencies. Am J Med. 79:1985;19-25.
23. Angeli P, Chiesa M, Caregaro L. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomised single blind clinical trial. Arch Intern Med. 151:1991;678-682.
24. Komsuoglu SS, Komsuoglu B, Osmenoglu M, Ozcan C, Gurhan H. Oral nifedipine in the treatment of hypertensive crises in patients with hypertensive encephalopathy. Int J Cardiol. 34:1992;277-282.
25. Takekoshi N, Murakami M, Murakami H. Treatment of severe hypertension and hypertensive emergency with nifedipine, a calcium antagonistic agent. Jpn Circ J. 45:1981;852-860.
26. Jariwalla AG, Anderson EG. Production of ischaemic cardiac pain by nifedipine. Br Med J. 1:1978;1181-1182.
27. O'Mailia JJ, Sander GE, Giles TD. Nifedipine associated myocardial ischaemia or infarction in the treatment of hypertensive urgencies. Ann Int Med. 107:1987;185-186.
28. Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch Intern Med. 147:1987;556-558.
29. Nobile-Orazio E, Sterzi R. Cerebral ischaemia after nifedipine treatment. Br Med J. 283:1981;948.
30. Bulling M, Burns R. Occipital cortical `angina' induced by nifedipine. Med J Austr. 148:1988;266.
31. Schwartz M, Naschitz JE, Heshurun D, Sharf B. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose. Arch Int Med. 150:1990;686-687.
32. Morton C, Hickey-Dwyer M. Cortical blindness after nifedipine treatment. Br Med J. 305:1992;693.
33. Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertenisve emergencies. Lancet. 338:1991;881.
34. Cheung JY, Bonventre JV, Malis CD, Leaf A. Calcium and ischaemic injury. N Engl J Med. 314:1986.
35. Grossman E, Messerli FH, Grodzicki T, Kowrey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 276:1996;1328-1331.
36. Circulation. 82:1990;664-707.
37. Conway J. Beta-blocking drug therapy in hypertension. Cardiovasc Clin. 9:1978;253-261.
38. Goldstein S. B-blockers in hypertensive and coronary heart disease. Arch Int Med. 156:1996;1267-1276.
39. Gibson DG. Pharmacodynamic properties of beta adrenergic receptor blocking drugs in man. Drugs. 7:1974;8-38.
40. Saxena PR. Beta-adrenoceptor antagonists and blood flow to the jeopardized myocardium. Eur Heart J. 4:1983;101-108.
41. Northcote RJ, Cooke MBD, Ballantyne D. The effect of chronic beta-blockade on left ventricular function: lack of influence of ISA in chronic stable angina pectoris. Clin Sci. 70:1986;242.
42. Gebhardt VA, Wisenberg G. The role of beta-blockade, with and without intrinsic sympathomimetic activity, in preserving compromised left ventricular function in patients with ischaemic heart disease. Am Heart J. 109:1985;1013-1020.
43. Cruickshank JM, Prichard BNC. Beta-blockers. Swales JD. Textbook of hypertension. 1994;1059-1088 Blackwell Scientific Publications, Oxford.
44. Held PH, Yusuf S. Effects of b-blockers in acute myocardial infarction. Eur Heart J. 14:1993;18-25.
45. Hjalmarson A, Elmfeldt D, Herlitz J. Effect on mortality of metoprolol in acute myocardial infarction. Lancet. 2:1981;823-827.
46. Eur Heart J. 6:1985;199-226.
47. Lancet. 2:1986;57-66.
48. N Engl J Med. 304:1981;801-807.
49. JAMA. 247:1982;1707-1714.
50. Gohlke P, Unger T. Angiotensin converting enzyme inhibitors. Swales JD. Textbook of Hypertension. 1994;1115-1127 Blackwell Scientific Publications, Oxford.
51. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1990;1161-1172.
52. McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 60:1988;117-124.
53. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med. 327:1992;669-677.
54. Lancet. 342:1993;821-828.
55. Am J Cardiol. 73:1994;44C-50C.
56. Ambrosioni E, Borghi C, Magnani B. The effect of angiotension-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
57. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med. 327:1992;678-684.
58. Lancet. 343:1994;1115-1122.
59. Lancet. 345:1995;669-685.
60. Lancet. 345:1995;686-687.
61. Saltissi S, Mushahwar SS. The management of acute myocardial infarction. Postgrad Med J. 71:1995;534-541.
62. Yusuf S, MacMahon S, Colins R, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomized trials. Lancet. i:1988;1088-1092.
63. Borchard U. Calcium antagonists in comparison: view of the pharmacologist. J Cardiovasc Pharmacol. 24:1994;S85-S91.
64. Wilcox RJ, Hampton JR, Banks DC. Trial of early nifedipine in acute myocardial infarction: the TRENT study. Br Med J. 293:1986;1204-1208.
65. Br Heart J. 56:1986;400-413.
66. Eur Heart J. 9:1988;354-364.
67. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. Arch Intern Med. 153:1993;345-353.
68. Gibson RS, Boden WE, Theroux P. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med. 315:1986;423-429.
69. N Engl J Med. 319:1988;385-392.
70. Eur Heart J. 5:1984;516-528.
71. Am J Cardiol. 66:1990;779-785.
72. Rengo F, Carbonin P, Pahor M. A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium antagonist Reinfarction Italian Study (CRIS). Am J Cardiol. 77:1996;365-369.
73. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J. 299:1989;1187-1192.
74. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 67:1991;1295-1297.
75. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
76. J Hypertens. 15:1997;105-115.
77. Myers MG, Raemsch KD. Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. J Cardiovasc Pharmacol. 10:1987;S76-S78.
78. Littler WA. Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard. Br J Clin Pharmacol. 30:1990;871-878.
79. Olivary MT, Bartorelli C, Polese A, Fiorentini C, Moruzi P, Guazi MD. Treatment of hypertension with nifedipine: a calcium antagonistic agent. Circulation. 59:1979;1056-1062.
80. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med. 155:1995;2150-2156.
81. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med. 323:1990;1177-1183.
82. Morris JL, Zaman AG, Smyllie JH, Campbell Cowan J. Nitrates in myocardial infarction: influence on infarct size, reperfusion, and ventricular remodelling. Br Heart J. 73:1995;310-319.